Israel Diabetes Market to be USD 457.53 Million by 2028, Propelled by Rising Obese Population & Growth in Sedentary Lifestyles
22 Feb, 2023

According to Renub Research's latest report, "Israel Diabetes Market, Size, Forecast 2023-2028, By Insulin Pump, CGM, Self-Monitoring Blood Device and Company Analysis" the Israel Diabetes Market is estimated to reach US$ 457.53 Million by 2028. In Israel, Diabetes is a leading cause of death. Diabetes is a long-term disease that rises when blood sugar is too high. The rising population, lack of physical activities, family background, increased awareness among people regarding medical treatment options, and unhealthy meals drive the market. However, the high costs of medicine and lack of reimbursement hinder the market. According to WHO data published in 2020, Diabetes Mellitus Deaths in Israel reached 1,913 total deaths.

The increasing population in Israel creates a primary Type-2 Diabetes disease. Israel Type 2 diabetes is considered an epidemic and continues rising. In Israel, the percentage of diabetes in the Arab population is twice that in the Jewish people. Also, Insulin dependent diabetics generally take Insulin by injection or using a pump. Diabetes can lead to cardiovascular disease, blindness, and kidney failure. To lower the increasing risk factors for diabetes, Israel could introduce efficient strategies that include population-wide measures and measures for high-risk individuals by using all available tools such as regulations, education, incentives, and health care programs.

Israel can further strengthen governance across the entire pathway of CVD and diabetes care. OECD countries are using a variety of policy instruments to improve the quality of services along the whole path, such as through the introduction of integrated care models, financial incentives for improved quality and performance, benchmarking, and target setting.

However, the age-adjusted mortality rate in Israel is low compared to most Western countries. However, mortality rates from diabetes and renal failure in Israel are amongst the highest, while those from cardiovascular diseases (CVD) are amongst the lowest. At young ages, Israel has one of the lowest rates of diabetes prevalence among European countries. However, for the intermediate age group of the IDF, 40–59, Israel's rank increased, and for the oldest age group, 60–79, the prevalence in Israel is among the highest, after Portugal (which had the next highest mortality rate from diabetes amongst European countries.

The age-standardized mortality rate from all causes of death is lacking in Israel compared to most OECD countries. Still, the corresponding rates for deaths from diabetes and kidney disease as the underlying cause (UC) are amongst the highest. In contrast, mortality rates from cardiovascular diseases (CVD), heart diseases, and cerebrovascular disease are low compared to other countries.

Increasing Numbers of Diabetic Patients in Israel make more demand for Insulin Pump Devices:-

The increasing population, the prevalence of being overweight, and obesity create more need for Insulin Pumps in such markets. Also, the demand for efficient insulin pumps has increased due to the development of very accurate glucose sensors and blood monitoring systems. Insulin pump therapy was developed to provide a more biological mode of insulin delivery to the insulin-requiring patient. First, the insulin pump uses only regular Insulin or rapid-acting insulin analogs, which provide a more consistent result. The OmniPod and the Omnipod DASH may be the most popular Insulin pump for individuals with Type 1 and Type 2 diabetes on the market.

Besides, SMBG and CMG will also dominate the Israeli market. Higher rates of self-monitored blood glucose (SMBG) testing, specifically when performed eight times per day or more, are associated with improvement. However, repeated daily SMBG fingerpick testing has many limitations, including poor compliance due to pain and discomfort and inaccurate readings due to improper user technique. Continuous glucose monitoring (CGM) systems, which measure glucose in the interstitial fluid, are demonstrated to be more effective than SMBG for monitoring. 

Competitive Landscape:-

Israel Diabetes companies include Insulet Corporation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, and Tandem Diabetes Care. 

• Sept 2022, Kadimastem Ltd. company developing treatments for ALS and diabetes, has been granted its third patent approval for the company's innovative cell selection and enrichment technology and its use in the production of IsletRx, the company's treatment and potential cure for diabetes.
• In June 2020, Tandem Diabetes Care and Abbott announced a collaboration to develop and commercialize integrated diabetes care solutions. These products will combine Abbott's continuous glucose monitoring technology with Tandem's ground-breaking insulin delivery devices to better diabetic blood sugar control.
• In Oct 2021, Medtronic was in negotiations to buy Israel-based insulin pump maker Triple Jump.

Market Summary:-

• By Devices: - The Report covers the United State Diabetes Market by devices from 3 viewpoints. 
• Self Monitoring Blood Glucose Devices (SMBG) (Test Strips Market, Lancet Market, Meter Market and Forecast, Blood Glucose (SMBG) Users and Blood Glucose Devices Reimbursement), 
• Continuous Glucose Monitoring (CGM) Device (Glucose Sensor Market, CGM Transmitter Market, CGM User, and Reimbursement Policies of CGM devices in Israel) 
• Insulin Pump (Insulin Pump Market, Insulin Pump User, and Reimbursement Policies Insulin Pump). 

About Us
Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys, and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Contact Us
Renub Research
Phone: +1-478-202-3244 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research